Sabrina Katzdobler1,2,3, Alexander Nitschmann4, Johannes Levin1,2,3, Matthias Brendel5,6,7, Henryk Barthel8, Gerard Bischof9,10, Leonie Beyer4, Ken Marek11,12, Mengmeng Song4, Olivia Wagemann1,2, Carla Palleis1,2,3, Endy Weidinger1,2, Anne Nack1, Urban Fietzek1, Carolin Kurz13, Jan Häckert13,14, Theresa Stapf13, Christian Ferschmann4, Maximilian Scheifele4, Florian Eckenweber4, Gloria Biechele4, Nicolai Franzmeier15, Anna Dewenter15, Sonja Schönecker1, Dorothee Saur16, Matthias L Schroeter17,18,19, Jost-Julian Rumpf16, Michael Rullmann8, Andreas Schildan8, Marianne Patt8, Andrew W Stephens20, Thilo van Eimeren9, Bernd Neumaier9,21, Alexander Drzezga9,10,22, Adrian Danek1,2, Joseph Classen16, Katharina Bürger15, Daniel Janowitz15, Boris-Stephan Rauchmann14,23, Sophia Stöcklein23, Robert Perneczky2,3,14,24, Florian Schöberl1, Andreas Zwergal1, Günter U Höglinger2,3,25, Peter Bartenstein3,4, Victor Villemagne26,27,28, John Seibyl11,12, Osama Sabri8. 1. Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany. 2. German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. 3. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 4. Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany. 5. German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. matthias.brendel@med.uni-muenchen.de. 6. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. matthias.brendel@med.uni-muenchen.de. 7. Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany. matthias.brendel@med.uni-muenchen.de. 8. Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany. 9. Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany. 10. Molecular Organization of the Brain, Institute for Neuroscience and Medicine, INM-2), Jülich, Germany. 11. InviCRO, LLC, Boston, MA, USA. 12. Molecular Neuroimaging, A Division of inviCRO, New Haven, CT, USA. 13. Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany. 14. Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, BKH Augsburg, Augsburg, Germany. 15. Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany. 16. Department of Neurology, University of Leipzig Medical Center, Leipzig, Germany. 17. Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany. 18. LIFE - Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany. 19. Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany. 20. Life Molecular Imaging GmbH, Berlin, Germany. 21. Institute for Neuroscience and Medicine (INM-3), Cognitive Neuroscience, Research Centre Juelich, Juelich, Germany. 22. German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. 23. Department of Radiology, University Hospital of Munich, LMU Munich, Munich, Germany. 24. Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College, London, UK. 25. Department of Neurology, Hannover Medical School, Hannover, Germany. 26. Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia. 27. Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia. 28. Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
PURPOSE: Early after [18F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [18F]PI-2620 tau-PET is able to discriminate the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome (4RTs) from disease controls and healthy controls. Here, we investigated whether early-phase [18F]PI-2620 PET has an additive value for biomarker based evaluation of 4RTs. METHODS: Seventy-eight patients with 4RTs (71 ± 7 years, 39 female), 79 patients with other neurodegenerative diseases (67 ± 12 years, 35 female) and twelve age-matched controls (69 ± 8 years, 8 female) underwent dynamic (0-60 min) [18F]PI-2620 PET imaging. Regional perfusion (0.5-2.5 min p.i.) and tau load (20-40 min p.i.) were measured in 246 predefined brain regions [standardized-uptake-value ratios (SUVr), cerebellar reference]. Regional SUVr were compared between 4RTs and controls by an ANOVA including false-discovery-rate (FDR, p < 0.01) correction. Hypoperfusion in resulting 4RT target regions was evaluated at the patient level in all patients (mean value - 2SD threshold). Additionally, perfusion and tau pattern expression levels were explored regarding their potential discriminatory value of 4RTs against other neurodegenerative disorders, including validation in an independent external dataset (n = 37), and correlated with clinical severity in 4RTs (PSP rating scale, MoCA, activities of daily living). RESULTS: Patients with 4RTs had significant hypoperfusion in 21/246 brain regions, most dominant in thalamus, caudate nucleus, and anterior cingulate cortex, fitting to the topology of the 4RT disease spectrum. However, single region hypoperfusion was not specific regarding the discrimination of patients with 4RTs against patients with other neurodegenerative diseases. In contrast, perfusion pattern expression showed promise for discrimination of patients with 4RTs from other neurodegenerative diseases (AUC: 0.850). Discrimination by the combined perfusion-tau pattern expression (AUC: 0.903) exceeded that of the sole tau pattern expression (AUC: 0.864) and the discriminatory power of the combined perfusion-tau pattern expression was replicated in the external dataset (AUC: 0.917). Perfusion but not tau pattern expression was associated with PSP rating scale (R = 0.402; p = 0.0012) and activities of daily living (R = - 0.431; p = 0.0005). CONCLUSION: [18F]PI-2620 perfusion imaging mirrors known topology of regional hypoperfusion in 4RTs. Single region hypoperfusion is not specific for 4RTs, but perfusion pattern expression may provide an additive value for the discrimination of 4RTs from other neurodegenerative diseases and correlates closer with clinical severity than tau pattern expression.
PURPOSE: Early after [18F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [18F]PI-2620 tau-PET is able to discriminate the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome (4RTs) from disease controls and healthy controls. Here, we investigated whether early-phase [18F]PI-2620 PET has an additive value for biomarker based evaluation of 4RTs. METHODS: Seventy-eight patients with 4RTs (71 ± 7 years, 39 female), 79 patients with other neurodegenerative diseases (67 ± 12 years, 35 female) and twelve age-matched controls (69 ± 8 years, 8 female) underwent dynamic (0-60 min) [18F]PI-2620 PET imaging. Regional perfusion (0.5-2.5 min p.i.) and tau load (20-40 min p.i.) were measured in 246 predefined brain regions [standardized-uptake-value ratios (SUVr), cerebellar reference]. Regional SUVr were compared between 4RTs and controls by an ANOVA including false-discovery-rate (FDR, p < 0.01) correction. Hypoperfusion in resulting 4RT target regions was evaluated at the patient level in all patients (mean value - 2SD threshold). Additionally, perfusion and tau pattern expression levels were explored regarding their potential discriminatory value of 4RTs against other neurodegenerative disorders, including validation in an independent external dataset (n = 37), and correlated with clinical severity in 4RTs (PSP rating scale, MoCA, activities of daily living). RESULTS: Patients with 4RTs had significant hypoperfusion in 21/246 brain regions, most dominant in thalamus, caudate nucleus, and anterior cingulate cortex, fitting to the topology of the 4RT disease spectrum. However, single region hypoperfusion was not specific regarding the discrimination of patients with 4RTs against patients with other neurodegenerative diseases. In contrast, perfusion pattern expression showed promise for discrimination of patients with 4RTs from other neurodegenerative diseases (AUC: 0.850). Discrimination by the combined perfusion-tau pattern expression (AUC: 0.903) exceeded that of the sole tau pattern expression (AUC: 0.864) and the discriminatory power of the combined perfusion-tau pattern expression was replicated in the external dataset (AUC: 0.917). Perfusion but not tau pattern expression was associated with PSP rating scale (R = 0.402; p = 0.0012) and activities of daily living (R = - 0.431; p = 0.0005). CONCLUSION: [18F]PI-2620 perfusion imaging mirrors known topology of regional hypoperfusion in 4RTs. Single region hypoperfusion is not specific for 4RTs, but perfusion pattern expression may provide an additive value for the discrimination of 4RTs from other neurodegenerative diseases and correlates closer with clinical severity than tau pattern expression.
Authors: Thomas W Rösler; Amir Tayaranian Marvian; Matthias Brendel; Niko-Petteri Nykänen; Matthias Höllerhage; Sigrid C Schwarz; Franziska Hopfner; Thomas Koeglsperger; Gesine Respondek; Kerstin Schweyer; Johannes Levin; Victor L Villemagne; Henryk Barthel; Osama Sabri; Ulrich Müller; Wassilios G Meissner; Gabor G Kovacs; Günter U Höglinger Journal: Prog Neurobiol Date: 2019-06-22 Impact factor: 11.685
Authors: Carla Palleis; Matthias Brendel; Johannes Levin; Günter U Höglinger; Anika Finze; Endy Weidinger; Kai Bötzel; Adrian Danek; Leonie Beyer; Alexander Nitschmann; Maike Kern; Gloria Biechele; Boris-Stephan Rauchmann; Jan Häckert; Matthias Höllerhage; Andrew W Stephens; Alexander Drzezga; Thilo van Eimeren; Victor L Villemagne; Andreas Schildan; Henryk Barthel; Marianne Patt; Osama Sabri; Peter Bartenstein; Robert Perneczky; Christian Haass Journal: Mov Disord Date: 2021-05-05 Impact factor: 10.338
Authors: Matteo Pardini; Edward D Huey; Salvatore Spina; William C Kreisl; Silvia Morbelli; Eric M Wassermann; Flavio Nobili; Bernardino Ghetti; Jordan Grafman Journal: Neurology Date: 2019-01-30 Impact factor: 9.910
Authors: Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan Journal: Mov Disord Date: 2017-05-03 Impact factor: 10.338
Authors: Matthias Brendel; Henryk Barthel; Thilo van Eimeren; Ken Marek; Leonie Beyer; Mengmeng Song; Carla Palleis; Mona Gehmeyr; Urban Fietzek; Gesine Respondek; Julia Sauerbeck; Alexander Nitschmann; Christian Zach; Jochen Hammes; Michael T Barbe; Oezguer Onur; Frank Jessen; Dorothee Saur; Matthias L Schroeter; Jost-Julian Rumpf; Michael Rullmann; Andreas Schildan; Marianne Patt; Bernd Neumaier; Olivier Barret; Jennifer Madonia; David S Russell; Andrew Stephens; Sigrun Roeber; Jochen Herms; Kai Bötzel; Joseph Classen; Peter Bartenstein; Victor Villemagne; Johannes Levin; Günter U Höglinger; Alexander Drzezga; John Seibyl; Osama Sabri Journal: JAMA Neurol Date: 2020-11-01 Impact factor: 18.302
Authors: Leonie Beyer; Alexander Nitschmann; Henryk Barthel; Thilo van Eimeren; Marcus Unterrainer; Julia Sauerbeck; Ken Marek; Mengmeng Song; Carla Palleis; Gesine Respondek; Jochen Hammes; Michael T Barbe; Özgür Onur; Frank Jessen; Dorothee Saur; Matthias L Schroeter; Jost-Julian Rumpf; Michael Rullmann; Andreas Schildan; Marianne Patt; Bernd Neumaier; Olivier Barret; Jennifer Madonia; David S Russell; Andrew W Stephens; Sigrun Roeber; Jochen Herms; Kai Bötzel; Johannes Levin; Joseph Classen; Günter U Höglinger; Peter Bartenstein; Victor Villemagne; Alexander Drzezga; John Seibyl; Osama Sabri; Matthias Brendel Journal: Eur J Nucl Med Mol Imaging Date: 2020-04-21 Impact factor: 9.236
Authors: Julia Schmitt; Carla Palleis; Julia Sauerbeck; Marcus Unterrainer; Stefanie Harris; Catharina Prix; Endy Weidinger; Sabrina Katzdobler; Olivia Wagemann; Adrian Danek; Leonie Beyer; Boris-Stephan Rauchmann; Axel Rominger; Mikael Simons; Peter Bartenstein; Robert Perneczky; Christian Haass; Johannes Levin; Günter U Höglinger; Matthias Brendel Journal: Front Aging Neurosci Date: 2021-05-13 Impact factor: 5.750
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Howard H Feldman; Giovanni B Frisoni; Harald Hampel; William J Jagust; Keith A Johnson; David S Knopman; Ronald C Petersen; Philip Scheltens; Reisa A Sperling; Bruno Dubois Journal: Neurology Date: 2016-07-01 Impact factor: 9.910